GlassScriptPhysician profile
Patrice Crane Storey
NPI 1609835388
$753.74
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $138 · 2021: $158 · 2022: $148.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $143.97 | 2019-2022 | |
| Cranial Technologies, INC | $120.55 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $100.09 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $98.60 | 2019 | |
| Glaxosmithkline, LLC. | $59.91 | 2019-2020 | |
| Phadia US INC. | $55.47 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.68 | 2020-2021 | |
| Genentech USA, INC. | $30.79 | 2019 | |
| Pfizer INC. | $22.80 | 2022 | |
| Ironshore Pharmaceuticals INC. | $22.73 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $20.04 | 2021 | |
| Seqirus USA INC | $14.23 | 2022 | |
| Adlon Therapeutics L.P. | $13.39 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.49 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrice Crane Storey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.